In other words, the price has increased by $0.00 from its previous closing price. On the day, 1483888 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of OSCR’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on March 22, 2024, initiated with a Outperform rating and assigned the stock a target price of $20.
On November 02, 2023, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $8 to $9.
BofA Securities Upgraded its Underperform to Neutral on June 06, 2023, whereas the target price for the stock was revised from $5.40 to $8.75.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 06 ’24 when Blackley Richard Scott sold 27,043 shares for $14.12 per share. The transaction valued at 381,847 led to the insider holds 614,316 shares of the business.
Quane Alessandrea C. sold 13,233 shares of OSCR for $186,850 on Mar 06 ’24. The EVP, Chief Insurance Officer now owns 212,850 shares after completing the transaction at $14.12 per share. On Mar 04 ’24, another insider, Baltrus Victoria, who serves as the Chief Accounting Officer of the company, sold 33,707 shares for $15.88 each. As a result, the insider received 535,267 and left with 118,111 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OSCR now has a Market Capitalization of 3.10B and an Enterprise Value of 1.53B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.53 while its Price-to-Book (P/B) ratio in mrq is 3.85. Its current Enterprise Value per Revenue stands at 0.26.
Stock Price History:
Over the past 52 weeks, OSCR has reached a high of $18.55, while it has fallen to a 52-week low of $3.22. The 50-Day Moving Average of the stock is 14.35, while the 200-Day Moving Average is calculated to be 9.04.
Shares Statistics:
It appears that OSCR traded 3.36M shares on average per day over the past three months and 2.39M shares per day over the past ten days. A total of 193.87M shares are outstanding, with a floating share count of 145.17M. Insiders hold about 36.81% of the company’s shares, while institutions hold 45.89% stake in the company. Shares short for OSCR as of Feb 29, 2024 were 5.44M with a Short Ratio of 1.62, compared to 6.33M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.37% and a Short% of Float of 3.32%.
Earnings Estimates
As of right now, 4 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0.27 for the current quarter, with a high estimate of $0.33 and a low estimate of $0.22, while EPS last year was -$0.18. The consensus estimate for the next quarter is $0.19, with high estimates of $0.27 and low estimates of $0.15.
Analysts are recommending an EPS of between -$0.07 and -$0.17 for the fiscal current year, implying an average EPS of -$0.11. EPS for the following year is $0.39, with 5 analysts recommending between $0.6 and $0.24.
Revenue Estimates
In the current quarter, 3 analysts expect revenue to total $2.01B. It ranges from a high estimate of $2.05B to a low estimate of $1.96B. As of the current estimate, Oscar Health Inc’s year-ago sales were $1.15B, an estimated increase of 75.50% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $2.1B, an increase of 37.80% less than the figure of $75.50% in the same quarter last year. There is a high estimate of $2.16B for the next quarter, whereas the lowest estimate is $2.05B.
A total of 3 analysts have provided revenue estimates for OSCR’s current fiscal year. The highest revenue estimate was $8.38B, while the lowest revenue estimate was $8.25B, resulting in an average revenue estimate of $8.33B. In the same quarter a year ago, actual revenue was $5.86B, up 42.20% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $9.64B in the next fiscal year. The high estimate is $10.08B and the low estimate is $9.25B. The average revenue growth estimate for next year is up 15.70% from the average revenue estimate for this year.
